Sahra-Amel Belambri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sahra-Amel Belambri has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Jamel El-Benna
Centre de Recherche sur l'Inflammation, Laboratoire d'Excellence Inflamex, Faculté de Médecine Xavier Bichat, Université de Paris INSERM U1149, CNRS EMR 8252, 75018 Paris, France
2 shared publications - Meriem- Dehbia Chabane
Laboratoire de Biochimie Analytiques et Biotechnologies Faculté des Sciences Biologiques & des Sciences Agronomiques Université Mouloud Mammeri De Tizi‐Ouzou Tizi‐Ouzou Algéria
2 shared publications - Nassima Senani
Laboratoire de Biochimie Analytiques et Biotechnologies Faculté des Sciences Biologiques & des Sciences Agronomiques Université Mouloud Mammeri De Tizi‐Ouzou Tizi‐Ouzou Algéria
2 shared publications - Pham My-Chan Dang
Centre de Recherche sur l'Inflammation, Laboratoire d'Excellence Inflamex, Faculté de Médecine Xavier Bichat, Université de Paris INSERM U1149, CNRS EMR 8252, 75018 Paris, France
2 shared publications - Samia Bedouhene
Laboratoire de Biochimie Analytiques et Biotechnologies Faculté des Sciences Biologiques & des Sciences Agronomiques Université Mouloud Mammeri De Tizi‐Ouzou Tizi‐Ouzou Algéria
2 shared publications - Tinhinane Rekeb
Laboratoire de Biochimie Analytiques et Biotechnologies Faculté des Sciences Biologiques & des Sciences Agronomiques Université Mouloud Mammeri De Tizi‐Ouzou Tizi‐Ouzou Algéria
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (11)
Dual Modulation of Coagulation and Inflammation by Algerian Apis mellifera intermissa Bee Venom: An Integrated In Vitro, In Vivo, and In Silico Study
Bee venom (BV) is a complex bioactive mixture traditionally used to treat inflammatory disorders. This study investigated the biochemical composition and biological activities of BV from Algerian Apis mellifera intermissa using integrated in vitro, in vivo, and in silico approaches. BV was chemically characterized (UV–vis spectroscopy, SDS–PAGE, RP‐HPLC) and evaluated in vitro for anticoagulant (prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT)) and antioxidant (DPPH, ABTS, FRAP) activities. Anti‐inflammatory activity was assessed in rats using a carrageenan‐induced paw edema model following a 4‐week prophylactic protocol (0.8 mg/kg, twice weekly). Molecular docking was performed to investigate interactions between BV components and coagulation factors, including tissue factor, factor IXa, and factor Xa. BV contained 79.5% proteins, significantly prolonged aPTT from 23 ± 1.2 to 37.4 ± 1.8 s at 20 µg /mL, and exhibited moderate antioxidant activity (ABTS IC 50 = 67.6 ± 2.82 µg /mL). BV reduced paw edema by up to 86 ± 6% within the first hour, exceeding the effect of aspirin. Docking predicted favorable PLA2‐FXa interactions (HADDOCK score: −110 ± 8.4). These findings suggest the complementary biological activities of A. mellifera intermissa BV and its potential role as a multifunctional modulator of thrombo‐inflammatory pathways.
- 11 November 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (11)
Open AccessDual Modulation of Coagulation and Inflammation by Algerian Apis mellifera intermissa Bee Venom: An Integrated In Vitro, In Vivo, and In Silico Study
Bee venom (BV) is a complex bioactive mixture traditionally used to treat inflammatory disorders. This study investigated the biochemical composition and biological activities of BV from Algerian Apis mellifera intermissa using integrated in vitro, in vivo, and in silico approaches. BV was chemically characterized (UV–vis spectroscopy, SDS–PAGE, RP‐HPLC) and evaluated in vitro for anticoagulant (prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT)) and antioxidant (DPPH, ABTS, FRAP) activities. Anti‐inflammatory activity was assessed in rats using a carrageenan‐induced paw edema model following a 4‐week prophylactic protocol (0.8 mg/kg, twice weekly). Molecular docking was performed to investigate interactions between BV components and coagulation factors, including tissue factor, factor IXa, and factor Xa. BV contained 79.5% proteins, significantly prolonged aPTT from 23 ± 1.2 to 37.4 ± 1.8 s at 20 µg /mL, and exhibited moderate antioxidant activity (ABTS IC 50 = 67.6 ± 2.82 µg /mL). BV reduced paw edema by up to 86 ± 6% within the first hour, exceeding the effect of aspirin. Docking predicted favorable PLA2‐FXa interactions (HADDOCK score: −110 ± 8.4). These findings suggest the complementary biological activities of A. mellifera intermissa BV and its potential role as a multifunctional modulator of thrombo‐inflammatory pathways.
- 15 June 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (13) , 6246-6261
Anti-inflammatory activity of orange peel aqueous extract and hesperidin: integrated evidence from neutrophil assays, in vivo models, and in silico analyses
Orange peel aqueous extract and its major compound hesperidin inhibit neutrophil oxidative burst, MPO release, and chemotaxis, reducing inflammation in a rat pleurisy model.
- 15 June 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (13) , 6246-6261
Anti-inflammatory activity of orange peel aqueous extract and hesperidin: integrated evidence from neutrophil assays, in vivo models, and in silico analyses
Orange peel aqueous extract and its major compound hesperidin inhibit neutrophil oxidative burst, MPO release, and chemotaxis, reducing inflammation in a rat pleurisy model.